The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient Enrolment
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced the completion of patient enrolment in the CLEAR cardiovascular outcomes trial. The trial is designed to evaluate whether treatment with bempedoic acid reduces the risk of cardiovascular events in patients who have, or are at high risk for, cardiovascular disease and have a prior adverse event history with statins that limit the use or dose of statin therapy.
CLEAR Outcomes is an event-driven trial and will conclude once the pre-determined number of primary cardiovascular endpoints occur; this is estimated to occur during the second half of 2022. Bempedoic acid and its fixed dose combination (FDC) tablet with ezetimibe are currently undergoing regulatory review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA).
“We are excited by the potential of bempedoic acid to help provide cardiovascular protection for people struggling to achieve low-density lipoprotein (LDL) cholesterol targets,” said Wolfgang Zierhut, MD, Head of Antithrombotic and Cardiovascular Medical Affairs Department at Daiichi Sankyo Europe. “The CLEAR Outcomes trial is a significant undertaking which will provide important information on how the LDL cholesterol lowering seen with bempedoic acid translates into an impact on cardiovascular risk.”
“Phase 3 clinical trials demonstrated that bempedoic acid produces clinically important reductions in LDL cholesterol as well as hsCRP, a key marker of inflammation associated with cardiovascular disease,” said Stephen Nicholls, MBBS, PhD, FRACP, FACC, FESC, FAHA, FCSANZ, co-principal investigator of CLEAR Outcomes, and Director of MonashHeart, Monash Health and Professor of Cardiology, Monash University. “The CLEAR cardiovascular outcomes trial builds on these results and will determine whether bempedoic acid can also reduce the risk of cardiovascular morbidity and mortality. Treatment of statin averse patients, like those enrolled in CLEAR Outcomes, represents a major unmet medical need that affects millions of patients.”
- ENDS -
Design of the CLEAR cardiovascular outcomes trial
CLEAR Outcomes is a Phase 3, event-driven, randomised, multicenter, double-blind, placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduces the risk of cardiovascular events. The primary endpoint of the study is the effect of bempedoic acid on major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation; also referred to as "four-component MACE"). CLEAR Outcomes is designed to provide 90% power to detect an approximately 15% relative risk reduction in the primary endpoint in the bempedoic acid treatment group as compared to the placebo group and is expected to complete with a minimum of 1,620 patients experiencing the primary endpoint.
Eligible patients at high risk (LDL-C >100 mg/dL in primary prevention) for cardiovascular disease or with cardiovascular disease (LDL-C between 100 mg/dL to 190 mg/dL in secondary prevention) and who are only able to tolerate less than the lowest approved daily starting dose of a statin were randomised to receive bempedoic acid 180 mg once-daily or placebo. The study enrolled 14,032 patients at over 1,200 sites in 32 countries.
For more information, go to clinicaltrials.gov: CLEAR Cardiovascular Outcomes Trial.
With a targeted mechanism of action, bempedoic acid is an oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver and thereby lowers circulating LDL-C levels.1,2 It is intended for patients with hypercholesterolaemia and/or at high risk of atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering despite maximally tolerated statin therapy.
Bempedoic acid has a unique, innovative mode of action, which is complimentary to other lipid-lowering therapies, such as statins.3 Due to its liver-specific mode of action, bempedoic acid has a reduced potential to induce the muscle-related side-effects associated with statin therapy and provide additional LDL-C lowering on top of statin monotherapy in clinical trials.2
Completed Phase 2 and Phase 3 studies conducted in almost 4,800 patients, and approximately 3,100 patients treated with bempedoic acid, have demonstrated: an additional 20% LDL-C lowering (placebo-corrected) when added to moderate-to-high intensity statin background treatment; 28% LDL-C lowering (placebo-corrected) when added to no-or-low intensity statin background treatment; up to 38% (placebo-corrected) LDL-C lowering when administered as a fixed dose combination with ezetimibe in patients on maximally tolerated statin therapy.1,2,4
Bempedoic acid (180 mg) and the bempedoic acid / ezetimibe fixed dose combination tablet (180 mg/10 mg) are currently under review by the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use and the U.S. Food and Drug Administration for LDL-C lowering in patients who are not yet at their target LDL-C level. Daiichi Sankyo Europe licensed exclusive commercialisation rights to these products in the European Economic Area and Switzerland from Esperion. Approval decisions are expected during the first half of 2020.
Bempedoic Acid / Ezetimibe FDC: https://www.daiichi-sankyo.eu/media/bempedoic
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
1 Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022–32.
2 Ballantyne CM, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis.2018;277:195–203.
3 Laufs U, et al. Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662.
4 Ballantyne, CM, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2019; doi 10.1177/2047487319864671.
Lydia Worms (Europe)
Daiichi Sankyo Europe GmbH
Communications & Product PR Europe
+49 (89) 7808751
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IWBI Announces New Co-chairs and More than 225 Members of the Task Force on COVID-19 and Other Respiratory Infections: Prevention and Preparedness, Resilience and Recovery7.4.2020 00:03:00 EEST | Press release
The International WELL Building Institute (IWBI) today announced the addition of four renowned industry, academic and public health leaders from the U.S., United Kingdom, China and Singapore as the newest co-chairs of its Task Force on COVID-19 and other Respiratory Infections: Prevention and Preparedness, Resilience and Recovery. They join expert co-chairs from the U.S. and others from China who will help define the critical role buildings, organizations and communities play in reducing the health burden from this and other infectious diseases. Adding to the expertise of the Task Force as co-chairs are Despina Katsikakis, international partner and head of occupier business performance at Cushman & Wakefield; Dr. Wang Qingqin, vice president of China Academy of Building Science (CABR); Dr. Lam Khee Poh, Provost's Chair professor of Architecture and Building and dean, School of Design And Environment, National University of Singapore, and Joanne Mahoney, chief operating officer at the S
CORRECTING and REPLACING Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy6.4.2020 20:58:00 EEST | Press release
Please replace the release with the following corrected version due to multiple revisions to the Octapharma boilerplate and inclusion of additional multimedia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200406005285/en/ GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complic
Cognite Awarded Google Cloud Technology Partner of the Year 2019 for Manufacturing6.4.2020 19:00:00 EEST | Press release
Cognite, a global industrial DataOps and AI software-as-a-service (SaaS) company, was announced as the 2019 Google Cloud Technology Partner of the Year for Manufacturing. Cognite currently supports the full-scale digital transformation of heavy-asset industries around the world, empowering industrial companies to save on costs, reduce environmental footprints to improve sustainability and increase profits made possible through Cognite Data Fusion (CDF). This international award recognizes one Partner that has implemented multiple Google Cloud technologies to demonstrate how they work together easily to deliver solutions based on individual customer needs. “We appreciate being recognized for creating value through our software products by turning historical and real-time industrial data into insights. We have seen a number of our manufacturing clients develop and deliver new digital services and even transform their business model as a result of using Cognite Data Fusion,” said Dr. John
Verimatrix Announces Server-side Watermarking Integration with Akamai Intelligent Edge Platform6.4.2020 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Paris:VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect content, devices, software and applications, today announced a partnership with Akamai, the intelligent edge platform for securing and delivering digital experiences, to offer global enterprise server-side watermarking capabilities. By using Verimatrix server-side Watermarking pre-integrated with Akamai's Intelligent Edge Platform, Akamai customers can take advantage of a highly efficient, powerful approach to ensure that their premium video content stays protected. The unauthorized redistribution of content, especially restreaming of live sports events, leads to millions of dollars in annual lost revenue. Verimatrix Watermarking consists of session-based, user-specific tracking and source identification, which allows operators to trace sources of pirated content in real time. It is robust against various attack types, includ
Alpega TMS Brings Together the Expertise of inet and Transwide6.4.2020 17:00:00 EEST | Press release
Alpega Group announces Alpega TMS, a union of inet and Transwide’s cloud-based Transportation Management Systems. The new software provides a uniquely scalable solution, designed to manage all levels of logistics complexity. At the same time, Alpega Group has been recognized as a Challenger in Gartner’s 2020 Magic Quadrant for Transportation Management Systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200406005391/en/ Alpega Group announces Alpega TMS, a union of inet and Transwide’s cloud-based Transportation Management Systems. The new software provides a uniquely scalable solution, designed to manage all levels of logistics complexity. At the same time, Alpega Group has been recognized as a Challenger in Gartner’s 2020 Magic Quadrant for Transportation Management Systems. (Photo: Business Wire) Alpega TMS is the combination of two of the market’s most innovative, established and trusted solutions. inet has long been
Brightcove Launches New Mobile App to Streamline Employee Communications via Video6.4.2020 16:00:00 EEST | Press release
Brightcove Inc. (NASDAQ:BCOV), the leading provider of cloud services for video, today announced Brightcove Engage™, a purpose-built application developed for internal communications professionals to inform employees using the most powerful and effective means of communication ever created: mobile video. With templates for quickly organizing content, analytics for monitoring engagement, and enterprise-grade security and stability, Brightcove Engage streamlines internal communications using the power of video. Studies have shown that employee engagement is highly related to positive business outcomes, therefore Brightcove Engage fills a significant market need by allowing employees to view content in a modern, interactive way. Merging the two most effective mediums of digital communications – video and mobile – Brightcove Engage empowers internal communications professionals to build branded mobile experiences and securely broadcast company-wide live events, like town halls, as well as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom